nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—NFKB1—Adaptive Immune System—CTSL—meningioma	0.00294	0.00294	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD34—meningioma	0.00292	0.00292	CbGpPWpGaD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—AKT1—meningioma	0.00291	0.00291	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—PDGFB—meningioma	0.00291	0.00291	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CTSL—meningioma	0.0029	0.0029	CbGpPWpGaD
Thalidomide—TNF—TWEAK Signaling Pathway—AKT1—meningioma	0.0029	0.0029	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—meningioma	0.00289	0.00289	CbGpPWpGaD
Thalidomide—NFKB1—Notch Signaling Pathway—AKT1—meningioma	0.00283	0.00283	CbGpPWpGaD
Thalidomide—NFKB1—Fc-epsilon receptor I signaling in mast cells—AKT1—meningioma	0.00283	0.00283	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—ERBB2—meningioma	0.00279	0.00279	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CTSL—meningioma	0.00279	0.00279	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AP1B1—meningioma	0.00277	0.00277	CbGpPWpGaD
Thalidomide—NFKB1—LPA receptor mediated events—AKT1—meningioma	0.00272	0.00272	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—AKT1—meningioma	0.00269	0.00269	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—ERBB2—meningioma	0.00267	0.00267	CbGpPWpGaD
Thalidomide—NFKB1—AGE/RAGE pathway—AKT1—meningioma	0.00265	0.00265	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—TP53—meningioma	0.00264	0.00264	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—ERBB2—meningioma	0.00263	0.00263	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AP1B1—meningioma	0.00263	0.00263	CbGpPWpGaD
Thalidomide—NFKB1—BCR signaling pathway—AKT1—meningioma	0.00262	0.00262	CbGpPWpGaD
Thalidomide—NFKB1—Rac1/Pak1/p38/MMP-2 pathway—AKT1—meningioma	0.00262	0.00262	CbGpPWpGaD
Thalidomide—TNF—Ceramide signaling pathway—AKT1—meningioma	0.00261	0.00261	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TP53—meningioma	0.00259	0.00259	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of Telomerase—AKT1—meningioma	0.00259	0.00259	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—meningioma	0.00257	0.00257	CbGpPWpGaD
Thalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—AKT1—meningioma	0.00253	0.00253	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—ERBB2—meningioma	0.00251	0.00251	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—TP53—meningioma	0.00251	0.00251	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—ERBB2—meningioma	0.0025	0.0025	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—PDGFB—meningioma	0.00249	0.00249	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—ERBB2—meningioma	0.00249	0.00249	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—ERBB2—meningioma	0.00247	0.00247	CbGpPWpGaD
Thalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—meningioma	0.00246	0.00246	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—ERBB2—meningioma	0.00245	0.00245	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—meningioma	0.00244	0.00244	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—TP53—meningioma	0.00243	0.00243	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AP1B1—meningioma	0.00242	0.00242	CbGpPWpGaD
Thalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—meningioma	0.00241	0.00241	CbGpPWpGaD
Thalidomide—NFKB1—Leptin signaling pathway—AKT1—meningioma	0.0024	0.0024	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—TP53—meningioma	0.00239	0.00239	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—PTEN—meningioma	0.00238	0.00238	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—PTEN—meningioma	0.00238	0.00238	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—PDGFB—meningioma	0.00237	0.00237	CbGpPWpGaD
Thalidomide—TNF—Cardiac Hypertrophic Response—AKT1—meningioma	0.00234	0.00234	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—ERBB2—meningioma	0.00233	0.00233	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—ERBB2—meningioma	0.00233	0.00233	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—ERBB2—meningioma	0.00233	0.00233	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—ERBB2—meningioma	0.00231	0.00231	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—ERBB2—meningioma	0.00231	0.00231	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—ERBB2—meningioma	0.00229	0.00229	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—PTEN—meningioma	0.00228	0.00228	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—ERBB2—meningioma	0.00228	0.00228	CbGpPWpGaD
Thalidomide—TNF—Caspase Cascade in Apoptosis—AKT1—meningioma	0.00227	0.00227	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—ERBB2—meningioma	0.00227	0.00227	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—PTEN—meningioma	0.00224	0.00224	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—AKT1—meningioma	0.00223	0.00223	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—PTEN—meningioma	0.00219	0.00219	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—AKT1—meningioma	0.00219	0.00219	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—AKT1—meningioma	0.00219	0.00219	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—ERBB2—meningioma	0.00215	0.00215	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—PTEN—meningioma	0.00214	0.00214	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—PTEN—meningioma	0.00213	0.00213	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—PTEN—meningioma	0.00212	0.00212	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—AKT1—meningioma	0.00212	0.00212	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—PTEN—meningioma	0.00211	0.00211	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—TP53—meningioma	0.0021	0.0021	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—PTEN—meningioma	0.00209	0.00209	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—PTEN—meningioma	0.00208	0.00208	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—AKT1—meningioma	0.00208	0.00208	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—TP53—meningioma	0.00207	0.00207	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—AKT1—meningioma	0.00207	0.00207	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—ERBB2—meningioma	0.00206	0.00206	CbGpPWpGaD
Thalidomide—FGFR2—Constitutive PI3K/AKT Signaling in Cancer—AKT1—meningioma	0.00204	0.00204	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—AKT1—meningioma	0.00204	0.00204	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—AKT1—meningioma	0.00204	0.00204	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—PTEN—meningioma	0.00198	0.00198	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—PTEN—meningioma	0.00198	0.00198	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—PTEN—meningioma	0.00198	0.00198	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—meningioma	0.00197	0.00197	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.00197	0.00197	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—PTEN—meningioma	0.00197	0.00197	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Receptor Signaling Pathway—AKT1—meningioma	0.00195	0.00195	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—PTEN—meningioma	0.00195	0.00195	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—PTEN—meningioma	0.00194	0.00194	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—PTEN—meningioma	0.00194	0.00194	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HES1—meningioma	0.00188	0.00188	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—AKT1—meningioma	0.00187	0.00187	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD34—meningioma	0.00187	0.00187	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—PTEN—meningioma	0.00184	0.00184	CbGpPWpGaD
Thalidomide—FGFR2—PI-3K cascade—AKT1—meningioma	0.00184	0.00184	CbGpPWpGaD
Thalidomide—FGFR2—PI3K/AKT activation—AKT1—meningioma	0.00179	0.00179	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CTSL—meningioma	0.00178	0.00178	CbGpPWpGaD
Thalidomide—FGFR2—GAB1 signalosome—AKT1—meningioma	0.00178	0.00178	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—AKT1—meningioma	0.00178	0.00178	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD34—meningioma	0.00177	0.00177	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—ERBB2—meningioma	0.00176	0.00176	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—PTEN—meningioma	0.00176	0.00176	CbGpPWpGaD
Thalidomide—FGFR2—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—meningioma	0.00174	0.00174	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CTSL—meningioma	0.00169	0.00169	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—ERBB2—meningioma	0.00167	0.00167	CbGpPWpGaD
Thalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—AKT1—meningioma	0.00167	0.00167	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—AKT1—meningioma	0.00167	0.00167	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—TP53—meningioma	0.00162	0.00162	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—ERBB2—meningioma	0.00159	0.00159	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—AKT1—meningioma	0.00155	0.00155	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—TP53—meningioma	0.0015	0.0015	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.0015	0.0015	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TP53—meningioma	0.00149	0.00149	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—AKT1—meningioma	0.00146	0.00146	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CST3—meningioma	0.00144	0.00144	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HES1—meningioma	0.00143	0.00143	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—AKT1—meningioma	0.00143	0.00143	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—PTEN—meningioma	0.00143	0.00143	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—PDGFB—meningioma	0.00142	0.00142	CbGpPWpGaD
Thalidomide—NFKB1—BDNF signaling pathway—AKT1—meningioma	0.00142	0.00142	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—meningioma	0.00137	0.00137	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—AKT1—meningioma	0.00137	0.00137	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—AKT1—meningioma	0.00137	0.00137	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—PDGFB—meningioma	0.00137	0.00137	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—PTEN—meningioma	0.00135	0.00135	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—PDGFB—meningioma	0.00135	0.00135	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—meningioma	0.00134	0.00134	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—AKT1—meningioma	0.00131	0.00131	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PDGFB—meningioma	0.0013	0.0013	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—AKT1—meningioma	0.00129	0.00129	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—AKT1—meningioma	0.00126	0.00126	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—AKT1—meningioma	0.00126	0.00126	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALAD—meningioma	0.00124	0.00124	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—AKT1—meningioma	0.00123	0.00123	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—AKT1—meningioma	0.00123	0.00123	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—AKT1—meningioma	0.00122	0.00122	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—AKT1—meningioma	0.00122	0.00122	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—meningioma	0.00121	0.00121	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—AKT1—meningioma	0.00121	0.00121	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AP1B1—meningioma	0.0012	0.0012	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—AKT1—meningioma	0.0012	0.0012	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—AKT1—meningioma	0.00114	0.00114	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—AKT1—meningioma	0.00114	0.00114	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—AKT1—meningioma	0.00114	0.00114	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	0.00113	0.00113	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—meningioma	0.00113	0.00113	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—AKT1—meningioma	0.00113	0.00113	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—AKT1—meningioma	0.00112	0.00112	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TSHB—meningioma	0.00112	0.00112	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—AKT1—meningioma	0.00112	0.00112	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—AKT1—meningioma	0.00112	0.00112	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—AKT1—meningioma	0.00111	0.00111	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—meningioma	0.00109	0.00109	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—ERBB2—meningioma	0.00108	0.00108	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TSHB—meningioma	0.00107	0.00107	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—AKT1—meningioma	0.00106	0.00106	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—meningioma	0.00104	0.00104	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—meningioma	0.00102	0.00102	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—AKT1—meningioma	0.00102	0.00102	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	0.00101	0.00101	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALAD—meningioma	0.000983	0.000983	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—AKT1—meningioma	0.000958	0.000958	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SMO—meningioma	0.000955	0.000955	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—ERBB2—meningioma	0.000953	0.000953	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—meningioma	0.000931	0.000931	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.000928	0.000928	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALAD—meningioma	0.000925	0.000925	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALAD—meningioma	0.000923	0.000923	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PGR—meningioma	0.000916	0.000916	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ERBB2—meningioma	0.000915	0.000915	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SMO—meningioma	0.000906	0.000906	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—ERBB2—meningioma	0.000904	0.000904	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALAD—meningioma	0.000872	0.000872	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PGR—meningioma	0.000869	0.000869	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ERBB2—meningioma	0.000868	0.000868	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	0.000864	0.000864	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HES1—meningioma	0.000848	0.000848	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PDGFB—meningioma	0.000828	0.000828	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—ERBB2—meningioma	0.000822	0.000822	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—AKT1—meningioma	0.000821	0.000821	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—PTEN—meningioma	0.000813	0.000813	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TSHB—meningioma	0.000798	0.000798	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PDGFB—meningioma	0.000786	0.000786	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—PTEN—meningioma	0.000781	0.000781	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—AKT1—meningioma	0.000779	0.000779	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—PTEN—meningioma	0.000771	0.000771	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PTEN—meningioma	0.000741	0.000741	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PDGFB—meningioma	0.000726	0.000726	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CST3—meningioma	0.000716	0.000716	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALAD—meningioma	0.000714	0.000714	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALAD—meningioma	0.000651	0.000651	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TSHB—meningioma	0.000633	0.000633	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—meningioma	0.000633	0.000633	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HES1—meningioma	0.000626	0.000626	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TSHB—meningioma	0.000596	0.000596	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TSHB—meningioma	0.000595	0.000595	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HES1—meningioma	0.000594	0.000594	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TSHB—meningioma	0.000562	0.000562	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALAD—meningioma	0.000556	0.000556	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ERBB2—meningioma	0.000555	0.000555	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PDGFB—meningioma	0.000536	0.000536	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	0.000535	0.000535	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—AKT1—meningioma	0.00053	0.00053	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERBB2—meningioma	0.000527	0.000527	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PDGFB—meningioma	0.000508	0.000508	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTEN—meningioma	0.000488	0.000488	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERBB2—meningioma	0.000486	0.000486	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PTEN—meningioma	0.000473	0.000473	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—AKT1—meningioma	0.000468	0.000468	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TSHB—meningioma	0.00046	0.00046	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—AKT1—meningioma	0.00045	0.00045	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PTEN—meningioma	0.000449	0.000449	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—AKT1—meningioma	0.000444	0.000444	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—AKT1—meningioma	0.000427	0.000427	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HES1—meningioma	0.000421	0.000421	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TSHB—meningioma	0.000419	0.000419	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTEN—meningioma	0.000415	0.000415	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—meningioma	0.000404	0.000404	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—meningioma	0.000387	0.000387	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PDGFB—meningioma	0.00036	0.00036	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB2—meningioma	0.000359	0.000359	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TSHB—meningioma	0.000358	0.000358	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—meningioma	0.000344	0.000344	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB2—meningioma	0.000341	0.000341	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTEN—meningioma	0.000306	0.000306	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTEN—meningioma	0.00029	0.00029	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—meningioma	0.000281	0.000281	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—meningioma	0.000273	0.000273	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—meningioma	0.000259	0.000259	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—meningioma	0.000256	0.000256	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB2—meningioma	0.000242	0.000242	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—meningioma	0.000239	0.000239	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—meningioma	0.000219	0.000219	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTEN—meningioma	0.000217	0.000217	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—meningioma	0.000209	0.000209	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTEN—meningioma	0.000206	0.000206	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—meningioma	0.000198	0.000198	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—meningioma	0.000176	0.000176	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTEN—meningioma	0.000172	0.000172	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—meningioma	0.000167	0.000167	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTEN—meningioma	0.000162	0.000162	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTEN—meningioma	0.000162	0.000162	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTEN—meningioma	0.000153	0.000153	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTEN—meningioma	0.000125	0.000125	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—meningioma	0.000125	0.000125	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—meningioma	0.000119	0.000119	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTEN—meningioma	0.000114	0.000114	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—meningioma	9.94e-05	9.94e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTEN—meningioma	9.76e-05	9.76e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—meningioma	9.36e-05	9.36e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—meningioma	9.34e-05	9.34e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—meningioma	8.82e-05	8.82e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—meningioma	7.22e-05	7.22e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—meningioma	6.58e-05	6.58e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—meningioma	5.63e-05	5.63e-05	CbGpPWpGaD
